293 related articles for article (PubMed ID: 29728516)
21. MR-based attenuation correction for PET/MRI neurological studies with continuous-valued attenuation coefficients for bone through a conversion from R2* to CT-Hounsfield units.
Juttukonda MR; Mersereau BG; Chen Y; Su Y; Rubin BG; Benzinger TLS; Lalush DS; An H
Neuroimage; 2015 May; 112():160-168. PubMed ID: 25776213
[TBL] [Abstract][Full Text] [Related]
22. Whole-Body PET/MR Imaging: Quantitative Evaluation of a Novel Model-Based MR Attenuation Correction Method Including Bone.
Paulus DH; Quick HH; Geppert C; Fenchel M; Zhan Y; Hermosillo G; Faul D; Boada F; Friedman KP; Koesters T
J Nucl Med; 2015 Jul; 56(7):1061-6. PubMed ID: 26025957
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.
Chen B; Wei P; Macapinlac HA; Lu Y
Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
25. PET Tracer
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
[No Abstract] [Full Text] [Related]
26. Comparison of segmentation-based attenuation correction methods for PET/MRI: evaluation of bone and liver standardized uptake value with oncologic PET/CT data.
Kim JH; Lee JS; Song IC; Lee DS
J Nucl Med; 2012 Dec; 53(12):1878-82. PubMed ID: 23081993
[TBL] [Abstract][Full Text] [Related]
27. Combined
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Giskeødegård GF; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
J Nucl Med; 2018 May; 59(5):762-768. PubMed ID: 28986510
[TBL] [Abstract][Full Text] [Related]
28. Description and assessment of a registration-based approach to include bones for attenuation correction of whole-body PET/MRI.
Marshall HR; Patrick J; Laidley D; Prato FS; Butler J; Théberge J; Thompson RT; Stodilka RZ
Med Phys; 2013 Aug; 40(8):082509. PubMed ID: 23927354
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of fluciclovine (
Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
[TBL] [Abstract][Full Text] [Related]
31. Segmentation-based attenuation correction in positron emission tomography/magnetic resonance: erroneous tissue identification and its impact on positron emission tomography interpretation.
Brendle C; Schmidt H; Oergel A; Bezrukov I; Mueller M; Schraml C; Pfannenberg C; la Fougère C; Nikolaou K; Schwenzer N
Invest Radiol; 2015 May; 50(5):339-46. PubMed ID: 25585210
[TBL] [Abstract][Full Text] [Related]
32. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
[No Abstract] [Full Text] [Related]
33. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
34. Review of
Gusman M; Aminsharifi JA; Peacock JG; Anderson SB; Clemenshaw MN; Banks KP
Radiographics; 2019; 39(3):822-841. PubMed ID: 31059396
[TBL] [Abstract][Full Text] [Related]
35. Detection of Additional Primary Neoplasms on
Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
[TBL] [Abstract][Full Text] [Related]
36. Quantitative analysis of MRI-guided attenuation correction techniques in time-of-flight brain PET/MRI.
Mehranian A; Arabi H; Zaidi H
Neuroimage; 2016 Apr; 130():123-133. PubMed ID: 26853602
[TBL] [Abstract][Full Text] [Related]
37. PET attenuation correction using synthetic CT from ultrashort echo-time MR imaging.
Roy S; Wang WT; Carass A; Prince JL; Butman JA; Pham DL
J Nucl Med; 2014 Dec; 55(12):2071-7. PubMed ID: 25413135
[TBL] [Abstract][Full Text] [Related]
38. Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR.
Oehmigen M; Lindemann ME; Gratz M; Kirchner J; Ruhlmann V; Umutlu L; Blumhagen JO; Fenchel M; Quick HH
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):642-653. PubMed ID: 29119237
[TBL] [Abstract][Full Text] [Related]
39. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
[TBL] [Abstract][Full Text] [Related]
40. Impact of
Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
